The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
aTyr Pharma Presents Research Demonstrating Effects Of Novel NRP2-Targeting Antibody, ATYR2810, On Tumor Associated Macrophages At The Society For Immunotherapy Of Cancer Annual Meeting
aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the Society for
aTyr Pharma Presents Research Demonstrating Effects Of Novel NRP2-Targeting Antibody, ATYR2810, On Tumor Associated Macrophages At Society For Immunotherapy Of Cancer Annual Meeting
aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the Society for
ATyr Pharma, Celcuity Shares See Volume; Traders Circulate TipRanks Article Titled ‘2 Cutting-Edge Biotech Stocks That Can Double in Value (Or More)’ Mentioning Both Stocks
https://www.tipranks.com/news/article/2-cutting-edge-biotech-stocks-that-can-double-in-value-or-more
Where aTyr Pharma Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on aTyr Pharma (NASDAQ:LIFE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
RBC Capital Initiates Coverage On aTyr Pharma with Outperform Rating, Announces Price Target of $22
RBC Capital analyst Kennen MacKay initiates coverage on aTyr Pharma (NASDAQ:LIFE) with a Outperform rating and announces Price Target of $22.
48 Biggest Movers From Friday
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday.